Dr. Reddy’s Publicizes the First-to-Market Launch of Over-the-Counter, Retailer-Model Equal of Allegra-D® 24 Hr within the U.S. Market

Rate this post

[ad_1]

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–$RDY #DRREDDY–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, together with its subsidiaries collectively known as “Dr. Reddy’s”) at the moment introduced the first-to-market launch of over-the-counter (OTC) Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Prolonged Launch Tablets, USP, the store-brand equal of Allegra-D® 24 HR within the U.S. market, as accredited by the U.S. Meals and Drug Administration (USFDA).

“The launch of Dr. Reddy’s Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Prolonged Launch Tablets, USP, is a vital addition to our higher respiratory portfolio of OTC merchandise,” says Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories. “This primary-to-market launch is a testomony to our deep capabilities and our continued efforts to carry prime quality, inexpensive store-brand alternate options for our prospects and sufferers.”

Dr. Reddy’s OTC Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Prolonged Launch Tablets, USP is an over-the-counter oral antihistamine and nasal decongestant for the short-term reduction of nasal and sinus congestion resulting from colds or allergy symptoms. It briefly relieves sneezing; runny nostril; itchy, watery eyes; and itchy nostril or throat resulting from allergy symptoms.

Allegra-D® 24 HR had U.S. retail gross sales of roughly $45 million as of Might 2022 in line with IRI*.

Dr. Reddy’s OTC Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Prolonged Launch Tablets, USP might be obtainable in 5-count, 10-count, and 15-count pack sizes.

Allegra-D® is a registered trademark of Aventisub LLC.

*IRI POS TOTAL US – Multi-Outlet (MULO) interval ending Might 15, 2022

RDY-0722-OTC

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an built-in pharmaceutical firm, dedicated to offering inexpensive and modern medicines for more healthy lives. Dr. Reddy’s gives a portfolio of services together with APIs, customized pharmaceutical companies, generics, biosimilars and differentiated formulations. Our main therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, ache administration and dermatology. Dr. Reddy’s operates in markets throughout the globe. Our main markets embrace – USA, India, Russia & CIS nations, and Europe. For extra info, go online to: www.drreddys.com

Disclaimer: This press launch might embrace statements of future expectations and different forward-looking statements which are primarily based on the administration’s present views and assumptions and contain identified or unknown dangers and uncertainties that would trigger precise outcomes, efficiency or occasions to vary materially from these expressed or implied in such statements. Along with statements that are forward-looking by motive of context, the phrases “might”, “will”, “ought to”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “proceed” and related expressions establish forward-looking statements. Precise outcomes, efficiency or occasions might differ materially from these in such statements resulting from with out limitation, (i) common financial circumstances comparable to efficiency of monetary markets, credit score defaults , forex change charges, rates of interest, persistency ranges and frequency / severity of insured loss occasions, (ii) mortality and morbidity ranges and tendencies, (iii) altering ranges of competitors and common aggressive elements, (iv) adjustments in legal guidelines and rules and within the insurance policies of central banks and/or governments, (v) the affect of acquisitions or reorganization, together with associated integration points, and (vi) the susceptibility of our business and the markets addressed by our, and our prospects’, services to financial downturns because of pure disasters, epidemics, pandemics or different widespread sickness, together with coronavirus (or COVID-19), and (vii) different dangers and uncertainties recognized in our public filings with the Securities and Alternate Fee, together with these listed below the “Threat Elements” and “Ahead-Trying Statements” sections of our Annual Report on Kind 20-F for the yr ended March 31, 2022. The corporate assumes no obligation to replace any info contained herein.

Contacts

INVESTOR RELATIONS
AMIT AGARWAL

amita@drreddys.com

MEDIA RELATIONS
USHA IYER

USHAIYER@DRREDDYS.COM

Copyright © acrofan/Enterprise Wire All Proper Reserved



[ad_2]

Supply hyperlink